Association of genotype-predicted thiopurine S-methyltransferase/nudix hydrolase 15 phenotypes with 6-mercaptopurine tolerability and hospitalization-related outcomes in Chinese pediatric acute lymphoblastic leukemia patients: a multicenter retrospective study
Pharmacogenetics and Genomics · 13.11.2026
DOI: 10.1097/fpc.0000000000000628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenetics and Genomics, online erschienen am 13.11.2026. Verfasst von Rong Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objective
This multicenter retrospective study aimed to investigate the association of genotype-predicted thiopurine S -methyltransferase ( TPMT ) and nudix hydrolase 15 ( NUDT15 ) phenotypes with 6-mercaptopurine (6-MP) treatment tolerance and hospitalization-related outcomes during high-dose methotrexate (HD-MTX) consolidation block in Chinese pediatric acute lymphoblastic leukemia (ALL) patients.
Methods
This study included 103 Chinese pediatric ALL patients. Genotypes were translated into Clinical Pharmacogenetics Implementation Consortium guideline-defined predicted metabolizer phenotypes, and patients were classified as predicted normal metabolizers ( n = 80) or predicted intermediate metabolizers ( n = 23). Data on 6-MP treatment tolerance and hospitalization-related outcomes were collected across four cycles of HD-MTX treatment. Longitudinal data were analyzed using linear and generalized linear mixed-effects models. To control the false discovery rate across the five prespecified primary outcomes in the mixed-effects modeling, multiple comparisons were adjusted using the Benjamini–Hochberg procedure. Benjamini–Hochberg-adjusted P values ( P adj ) < 0.05 were considered statistically significant.
Results
Baseline characteristics were comparable between the predicted normal metabolizers and intermediate metabolizer groups. The body surface area–adjusted 6-MP total dose was consistently lower in the intermediate metabolizer group across all four cycles. Longitudinal analysis confirmed that intermediate metabolizer patients experienced significantly longer inpatient stays ( β = 0.98 days, P adj = 0.033), a higher risk of chemotherapy delay [odds ratio (OR) = 2.86, P adj = 0.02], and an increased likelihood of unplanned readmission (OR = 3.75, P adj = 0.018). Intermediate metabolizer status was not significantly associated with infection risk.
Conclusion
In this retrospective cohort, genotype-predicted TPMT/NUDT15 intermediate metabolizer status was associated with lower prescribed 6-MP dose intensity and worse hospitalization-related outcomes during HD-MTX consolidation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Oncology.
- Department of Pharmacy, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), Fuzhou.
- Department of Pediatric Hematology, Rheumatology and Nephrology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou.
- Department of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen.
- Department of Pediatrics, Quanzhou First Hospital, Quanzhou.
- Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Zitieren
APA
Hu, R., Lin, P., Weng, K., Guo, B., Zhuang, S., Chen, Z., Wang, Y., Wang, X., Zhang, H., & He, Y. (2026). Association of genotype-predicted thiopurine S-methyltransferase/nudix hydrolase 15 phenotypes with 6-mercaptopurine tolerability and hospitalization-related outcomes in Chinese pediatric acute lymphoblastic leukemia patients: a multicenter retrospective study. Pharmacogenetics and Genomics. https://doi.org/10.1097/fpc.0000000000000628
Vancouver
Hu R, Lin P, Weng K, Guo B, Zhuang S, Chen Z, et al. Association of genotype-predicted thiopurine S-methyltransferase/nudix hydrolase 15 phenotypes with 6-mercaptopurine tolerability and hospitalization-related outcomes in Chinese pediatric acute lymphoblastic leukemia patients: a multicenter retrospective study. Pharmacogenetics and Genomics. 2026. doi:10.1097/fpc.0000000000000628
BibTeX
@article{Hu2026,
author = {Hu, Rong and Lin, Ping and Weng, Kaizhi and Guo, Biyun and Zhuang, Shuquan and Chen, Zhiyuan and Wang, Yue and Wang, Xiaofang and Zhang, Hui and He, Yingyi},
title = {Association of genotype-predicted thiopurine S-methyltransferase/nudix hydrolase 15 phenotypes with 6-mercaptopurine tolerability and hospitalization-related outcomes in Chinese pediatric acute lymphoblastic leukemia patients: a multicenter retrospective study},
journal = {Pharmacogenetics and Genomics},
year = {2026},
doi = {10.1097/fpc.0000000000000628}
}
EUVIMED